Defining the brain circuits involved in psychiatric disorders: IMI-NEWMEDS
- 4 November 2016
- journal article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 16 (1) , 1-2
Abstract
Despite the vast amount of research on schizophrenia and depression in the past two decades, there have been few innovative drugs to treat these disorders. Precompetitive research collaborations between companies and academic groups can help tackle this innovation deficit, as illustrated by the achievements of the IMI-NEWMEDS consortium.Keywords
This publication has 5 references indexed in Scilit:
- Phencyclidine-induced disruption of oscillatory activity in prefrontal cortex: Effects of antipsychotic drugs and receptor ligandsEuropean Neuropsychopharmacology, 2016
- Acute ketamine challenge increases resting state prefrontal-hippocampal connectivity in both humans and ratsPsychopharmacology, 2015
- Phencyclidine Inhibits the Activity of Thalamic Reticular Gamma-Aminobutyric Acidergic Neurons in Rat BrainBiological Psychiatry, 2014
- The hippocampal–prefrontal pathway: The weak link in psychiatric disorders?European Neuropsychopharmacology, 2013
- Activation of Thalamocortical Networks by the N-methyl-D-aspartate Receptor Antagonist Phencyclidine: Reversal by ClozapineBiological Psychiatry, 2011